Literature DB >> 25834519

Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.

Musa Waiswa1, Emmanuel Seremba1, Ponsiana Ocama1, Henry Ddungu1, Keneth Opio1, Clement Okello1, Timothy O'shea2, Madeleine Verhovsek2, Richard Mutyabule3.   

Abstract

INTRODUCTION: Splanchnic venous thrombosis (SVT) has varied etiology with Philadelphia-negative myeloproliferative neoplasms (MPNs) being the most frequent underlying prothrombotic factor. Hematological indices often remain within normal range because of portal hypertension and its sequelae, causing diagnostic challenges. The high frequency of JAK2 mutation among patients with SVT reinforces the diagnostic utility of JAK2V617F testing. CASE REPORT: We report a case of a 62-year-old black man with progressive abdominal swelling and features of decompensated chronic liver disease found to have SVT-portal vein thrombosis and how JAK2 V617F was useful in unmasking an underlying myeloproliferative neoplasm.
CONCLUSION: A high index of suspicion for an underlying prothrombotic factor is critical for patients presenting with thrombosis in unusual sites. This is useful in prognostic stratification and patient outcomes. JAK2 mutation screening is now part of the standard diagnostic workup in SVT.

Entities:  

Keywords:  myeloproliferative neoplasm; venous thrombosis

Mesh:

Substances:

Year:  2014        PMID: 25834519      PMCID: PMC4370089          DOI: 10.4314/ahs.v14i4.39

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  17 in total

1.  Detection of thrombosis in the portal venous system: comparison of contrast-enhanced MR angiography with intraarterial digital subtraction angiography.

Authors:  B Kreft; H Strunk; S Flacke; M Wolff; R Conrad; J Gieseke; D Pauleit; R Bachmann; A Hirner; H H Schild
Journal:  Radiology       Date:  2000-07       Impact factor: 11.105

2.  Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2010-06-27       Impact factor: 25.083

3.  Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.

Authors:  B Condat; F Pessione; S Hillaire; M H Denninger; M C Guillin; M Poliquin; A Hadengue; S Erlinger; D Valla
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

4.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 5.  Clinical approach to splanchnic vein thrombosis: risk factors and treatment.

Authors:  Nicoletta Riva; Marco P Donadini; Francesco Dentali; Alessandro Squizzato; Walter Ageno
Journal:  Thromb Res       Date:  2012-10       Impact factor: 3.944

Review 6.  Acute thrombosis of the splanchnic veins.

Authors:  P Gertsch; J Matthews; J Lerut; P Luder; L H Blumgart
Journal:  Arch Surg       Date:  1993-03

7.  Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms.

Authors:  J Hoekstra; E L Bresser; J H Smalberg; M C W Spaander; F W G Leebeek; H L A Janssen
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

Review 8.  Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.

Authors:  V De Stefano; L Teofili; G Leone; J J Michiels
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

9.  Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.

Authors:  Amarapurkar Deepak; Sundeep Punamiya; Nikhil Patel; Sunil Parekh; Shilpa Mehta; Nirali Shah
Journal:  Trop Gastroenterol       Date:  2011 Oct-Dec

10.  Causes of adult splanchnic vein thrombosis in the mediterranean area.

Authors:  Valerio De Stefano; Tommaso Za; Angela Ciminello; Silvia Betti; Elena Rossi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-19       Impact factor: 2.576

View more
  1 in total

1.  Editorial.

Authors:  James Tumwine
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.